Literature DB >> 24210888

Stress-related cardiomyopathy, ventricular dysfunction, artery thrombosis: a hidden pheochromocytoma.

Anna Battimelli1, Maria Vincenza Polito2, Marco Di Maio3, Susanna Poto4, Luciana Pierro5, Domenico Caggiano6, Federico Piscione7.   

Abstract

Clinical presentation of pheochromocytoma can vary, and it can sometimes mimic other diseases. Some patients with pheochromocytoma may have atypical presentations, such as clinical features consistent with an acute coronary syndrome, that only later suggest a classical picture of stress-related cardiomyopathy. To our best knowledge, pheochromocytoma has been incidentally revealed in a few cases of catecholamine-induced cardiomyopathy and in only 1 case of peripheral arterial thrombosis. This is the first case of pheochromocytoma revealed after left ventricular dysfunction caused by stress-related cardiomyopathy associated with inferior limb artery thrombosis in a patient with a complex cardiovascular history.

Entities:  

Mesh:

Year:  2013        PMID: 24210888     DOI: 10.1016/j.ajem.2013.09.034

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

Review 1.  Thrombo-embolic complications in takotsubo syndrome: Review and demonstration of an illustrative case.

Authors:  Shams Y-Hassan; Staffan Holmin; Goran Abdula; Felix Böhm
Journal:  Clin Cardiol       Date:  2019-01-03       Impact factor: 2.882

2.  Adrenergic Shock Presenting with Atypical Takotsubo Syndrome: The Alliance Between Levosimendan and Intraaortic Balloon Pump Against the Pheochromocytoma.

Authors:  Maria Vincenza Polito; Elena De Angelis; Andreas Hagendorff; Alessandro Puzziello; Francesco Vigorito; Amelia Ravera
Journal:  Anatol J Cardiol       Date:  2022-04       Impact factor: 1.475

3.  Reply to Letter to the Editor: "Pheochromocytoma and Takotsubo Syndrome: An Ominous Duo".

Authors:  Maria Vincenza Polito; Elena De Angelis; Amelia Ravera
Journal:  Anatol J Cardiol       Date:  2022-08       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.